International Journal of Environmental Sciences
ISSN: 2229-7359
Vol. 11 No. 24s, 2025
https://theaspd.com/index.php

Phytochemistry And Pharmacological Potential Of Piper Methysticum: Influence Of Plant Parts And Implications For Neurodegenerative Disorders

Neha Tamta*[1], Dr. Abhijeet Ojha[2], Ms. Rachana Belwal[3], Dr. Amit Chaudhary[4], Mr. Panshul Chauhan[5], Dr. Kalpesh Gaur[6], Dr. Jatin Jaiswal[7], Dr. Sudhakar Kaushik[8], Mr. Sandeep Kumar Tyagi[9]

[1]Neha Tamta, Assistant Professor, Faculty of Pharmacy, IFTM University, Lodhipur Rajput, Moradabad, Uttar Pradesh, India, Pin Code - 244001

[2]Dr. Abhijeet Ojha, Professor and Principal, Faculty of Pharmaceutical Sciences, Amrapali University, Haldwani, Uttarakhand, India, Pin Code-263139

[3]Ms. Rachana Belwal, Assistant Professor, Department of Pharmaceutical Chemistry, School of Pharmacy and Research, Dev Bhoomi Uttarakhand University,
Dehradun, Uttarakhand, India, Pin Code-248007

[4]Dr. Amit Chaudhary, Professor, Chitkara University School of Pharmacy, Chitkara University, Baddi, Himanchal Pradesh, Solan, India, Pin Code- 174103

[5]Mr. Panshul Chauhan, Assistant Professor, Integrated Academy of Management and Technology, Ghaziabad, Uttar Pradesh, India, Pin Code- 201013

[6]Dr. Kalpesh Gaur, Professor, Geetanjali Institute of Pharmacy, Geetanjali University, Udaipur, Rajasthan, India, Pin Code – 313003

[7]Dr. Jatin Jaiswal, Professor, Faculty of Pharmacy, Future Institute of Medical Sciences, Future University, Bareilly, Uttar Pradesh, India, Pin Code-243503

[8]Dr. Sudhakar Kaushik, Associate Professor, School of Pharmaceutical Sciences, Shri Guru Ram Rai University, Dehradun, Uttarakhand, India, Pin Code-248001

[9]Mr. Sandeep Kumar Tyagi, Assistant Professor, School of Basic Sciences and Technology, IIMT University Meerut, 'O' Pocket Ganga Nagar, Meerut, Uttar Pradesh, India, Pin Code-250002

ABSTRACT:

In the past few years, there has been an increasing fascination with the healing possibilities of herbal remedies, especially in tackling conditions associated with the central nervous system (CNS), including neurodegenerative ailments and anxiety-related issues. In contrast to synthetic pharmaceuticals, herbal remedies typically exhibit a reduced incidence of side effects and tend to be more economical. Among these, Piper methysticum has attracted interest because of its diverse array of bioactive constituents, such as kavalactones, flavokavains, alkaloids, tannins, and terpenoids. The components play a significant role in its therapeutic effects, encompassing sedative, anxiolytic, neuroprotective, and muscle-relaxing characteristics. This analysis thoroughly investigates the phytochemical makeup of Piper methysticum, its pharmacokinetics, modes of action, and therapeutic possibilities in neuropsychiatric conditions. The physiological impacts of kava are primarily linked to its engagement with γ-aminobutyric acid (GABA) receptors, suppression of monoamine oxidase B (MAO-B), adjustment of calcium and sodium ion channels, and its effect on essential neurotransmitters including dopamine, serotonin, and norepinephrine. Recent research has additionally investigated its possibilities in pain relief, anticonvulsant effects, and cancer therapy. Nonetheless, apprehensions about the hepatotoxic effects and safety characteristics of various kava formulations demand additional clinical and toxicological research. This evaluation emphasises the existing understanding of Piper methysticum, points out deficiencies in research, and explores its promise as a bioactive agent for central nervous system disorders and various therapeutic uses.

Keywords: *Piper methysticum, kava-kava, kavalactones, phytochemistry, neuroprotection, anxiolytic, bioactive compounds, CNS disorders.*

1. INTRODUCTION

The growing interest in herbal medicine stems from its potential as a safer and more accessible alternative to synthetic pharmaceuticals. Medicinal plants contain a wide range of bioactive compounds that exhibit therapeutic effects, particularly in neurological and psychiatric disorders [1]. *Piper methysticum*, commonly known as kava or kava-kava, is one such plant that has been used for centuries by Pacific Island cultures for its anxiolytic, sedative, and muscle-relaxant properties [2]. Traditionally, kava has been consumed as

a beverage prepared from the roots of the plant, often used in social and ceremonial contexts to promote relaxation, sociability, and mental clarity [3]. In recent decades, its pharmacological potential has gained significant attention, particularly for its role in managing anxiety disorders, stress, and insomnia [4]. Historically, *Piper methysticum* has been a central part of Pacific Islander traditions, where it is valued not only for its psychoactive properties but also for its purported medicinal benefits [5]. Indigenous communities have long utilized kava to relieve pain, reduce fatigue, treat urinary tract infections, and manage menstrual discomfort [6]. The plant's roots and rhizomes, rich in bioactive compounds, are known for their calming and muscle-relaxing effects, which have made kava an integral part of both social and therapeutic practices [7]. In modern medicine, kava has been explored as a natural alternative to pharmaceutical anxiolytics such as benzodiazepines. Unlike these synthetic drugs, which often cause cognitive impairment and dependency, kava appears to offer relaxation without significant sedation or addiction potential [8].Research suggests that kava's anxiolytic effects are comparable to standard treatments for anxiety, making it a promising candidate for further clinical applications [9], [10], [11]. These compounds interact with the central nervous system (CNS) by modulating neurotransmitter activity, particularly through their interaction with γ-aminobutyric acid (GABA) receptors [12]. This mechanism enhances inhibitory signaling in the brain, producing anxiolytic and sedative effects without the cognitive dulling associated with conventional sedatives [13].Kavalactones also influence voltage-gated sodium and calcium ion channels, contributing to their anticonvulsant and muscle-relaxant properties [14].Furthermore, kava has been shown to inhibit monoamine oxidase B (MAO-B), an enzyme involved in neurotransmitter metabolism, leading to increased levels of dopamine and serotonin-neurotransmitters associated with mood regulation [15]. This suggests potential applications in mood disorders, including depression and stress-related conditions [16]. Beyond its impact on the CNS, kava exhibits anti-inflammatory, analgesic, and antioxidant properties, which may further contribute to its therapeutic potential [17]. Some studies have even explored its use in cancer prevention and treatment, as certain kavalactones and flavokavains have demonstrated cytotoxic effects against cancer cells [18].Despite its medicinal potential, kava has been the subject of controversy due to concerns regarding hepatotoxicity. Reports of liver toxicity associated with kava use led to regulatory restrictions in several countries, particularly in the early 2000s [19]. However, recent studies indicate that liver damage may be linked to factors such as the extraction method, the quality of raw materials, and improper consumption rather than an inherent toxicity of the plant itself [20]. Traditional water-based preparations appear to be safer compared to alcohol- or acetoneextracted kava products, which may contain harmful alkaloids [21]. Further research is needed to clarify the pharmacokinetics, long-term safety, and potential interactions of kava with other drugs. Standardization of kava extracts, along with clinical trials evaluating its efficacy in diverse populations, will be crucial in determining its role in modern medicine [22].This review aims to provide a comprehensive analysis of *Piper methysticum*, focusing on its phytochemical composition, pharmacological properties, mechanisms of action, and therapeutic applications. Additionally, it highlights the safety concerns surrounding kava consumption and identifies key areas for future research to optimize its medicinal use.

2. BOTANICAL DESCRIPTION

Fig. (1). *Piper methysticum*

It is primarily cultivated in the South Pacific, particularly in Vanuatu, Fiji, Tonga, Samoa, and the Santa Cruz Islands, where it has been an integral part of traditional medicine and cultural practices [13].The plant is dioecious, meaning individual plants are either male or female, which limits its natural reproduction as female plants rarely produce viable seeds. Consequently, kava is propagated vegetatively through stem cuttings [14].

2.1. Morphology and Growth Characteristics

Kava typically grows between 2 to 3 meters in height, developing a woody base with numerous lateral branches. The stem is stout and nodular, featuring distinctive internodes that store water and nutrients essential for the plant's growth [15]. Leaves of *Piper methysticum* are broadly ovate to heart-shaped (cordate), with a length of 13–28 cm and a width of 10–22 cm. They possess 9 to 13 prominent veins radiating from the base, and their surface is smooth with slightly wavy margins. Each leaf is supported by a short petiole, and large stipules are present at the base, aiding in protection and structural support [16].The inflorescence consists of small, spike-like flower clusters measuring 3 to 9 cm in length. The flowers are minute, inconspicuous, and lack petals. Due to its dioecious nature, kava rarely produces fertile seeds, relying entirely on human cultivation through cuttings for propagation [17].

2.2. Root and Rhizome Structure

The root system of kava is highly developed, forming thick, fibrous, and branching rhizomes that penetrate deep into the soil. A mature plant typically weighs between 2 to 10 kg, with its rhizomes making up a significant portion of the biomass. The rhizomes are rugged, light brown, and contain high concentrations of bioactive compounds responsible for kava's pharmacological effects [18]. Kava rhizomes vary in size, typically measuring 3 to 20 cm in length and 1 to 5 cm in width. The outer layers of the rhizome contain fibrous tissues, while the inner portions are rich in kavalactones and other secondary metabolites. Traditionally, the rhizomes are dried and ground into a powder to prepare kava beverages or extracts [19].

2.3. Phytochemical Composition

The primary bioactive constituents of *Piper methysticum* are kavalactones, along with flavokavains, alkaloids, tannins, and other secondary metabolites. The root and rhizome contain approximately 43% starch, 20% fibers,3–20% kavalactones (the main psychoactive components) 3.2% sugars, 3.6% proteins 3.2% minerals (potassium, calcium, magnesium, sodium, aluminium, and iron) Dihydrochalcones (flavokavains A, B, and C) Alkaloids such as pipermethystine (which may contribute to hepatotoxic effects).

Key Bioactive Compounds: Among the six major kavalactones, the most pharmacologically significant include: Yangonin, 5,6,7,8-Tetrahydroyangonin, 5,6-Dihydroyangonin, Kavain, Dihydrokavain, Methysticin, Dihydromethysticin.

These compounds contribute to kava's anxiolytic, sedative, anticonvulsant, and musclerelaxant properties by interacting with GABA receptors, modulating dopamine levels, and influencing voltage-gated ion channels [20].

Additional Phytochemicals: In addition to kavalactones, *Piper methysticum* contains flavonoids, chalcones, and various organic acids, including: Flavokavains A, B, and C, Dihydrokavain-5-ol, Cuproic acid, Methylenedioxy-3,4-cinnamalketone, Benzoic acid, cinnamic acid, and phenylacetic acid, Pipermethystine (a minor alkaloid with potential hepatotoxic effects).

2.4. Geographical Distribution and Habitat

Kava is native to the South Pacific and thrives in warm, humid climates with well-drained volcanic soil. It is predominantly cultivated in Vanuatu, Fiji, Samoa, Tonga, Papua New Guinea, and the Solomon Islands,where traditional cultivation methods are preserved [21]. Kava plants require partial shade, high organic matter content in the soil, and consistent rainfall to flourish. Unlike other members of the *Piper* genus, kava does not produce viable seeds and must be propagated manually, making it highly dependent on human intervention for survival [22].The botanical features of *Piper methysticum* are closely linked to its pharmacological properties. The rhizome and root system serve as the primary reservoir of kavalactones, which are responsible for kava's anxiolytic and sedative effects. However, variations in cultivar type, growing conditions, and extraction methods influence the chemical composition and potency of kava preparations. Understanding the botanical characteristics and phytochemistry of *Piper methysticum* is crucial for optimizing its medicinal applications and ensuring safe consumption.

2.5. Taxonomic classification of *Piper methysticum*

Kingdom	-	Plantae
Binomial name	-	*Piper methysticum*
Class	-	Dicotyledonae
Order	-	Piperales G. Forst
Family	-	Piperaceae
Genus	-	Piper
Species	-	*P. Methysticum*

3.1 ROLE OF PLANT PARTS IN BIOACTIVITY

The chemical profile of kava extracts is highly dependent on the specific plant organ utilized. Each part of the plant contains different proportions of kavalactones, alkaloids, and other phytochemicals, leading to variability in medicinal properties and safety profiles [23].

3.2 Roots and Rhizomes

The roots and rhizomes of *Piper methysticum* are the primary sources of kavalactones, making them the preferred part for medicinal use. Clinical research has focused primarily on rootderived extracts, as they are rich in psychoactive kavalactones such as kavain, yangonin, and methysticin, which exhibit anxiolytic, sedative, and neuroprotective effects [24]. These plant parts also contain flavokavains, albeit in lower concentrations than in the stems and leaves.

It has been suggested that peeling the outer layers of the roots before extraction may reduce the presence of potentially hepatotoxic alkaloids, thereby minimizing liver-related side effects [25].

3.3 Leaves

The leaves of *Piper methysticum* contain higher amounts of flavonoids, tannins, and terpenoids compared to the roots. While these compounds contribute to antioxidant and anti-inflammatory properties, the leaves are not traditionally used in kava preparations due to their high alkaloid content, particularly pipermethystine, which has been associated with hepatotoxicity in experimental studies [26]. Although kava leaf extracts have been shown to interact strongly with CNS receptors in vitro, their pharmacological effects remain underexplored due to safety concerns [27].

3.4 Stems

The stems contain lower concentrations of kavalactones but have higher alkaloid levels, making them less suitable for medicinal use. Some commercial kava preparations include basal stem peelings, but excessive stem content may increase toxicity risks due to the presence of pipermethystine and other potentially harmful alkaloids [28].

3.5.1 Extraction Methods and Their Influence on Kava's Bioactivity and Safety

In addition to plant part selection and cultivar type, the extraction method plays a critical role in determining the safety and efficacy of kava preparations. Different extraction techniques yield varying concentrations of kavalactones, flavokavains, and alkaloids, influencing both therapeutic potency and toxicity risks [29]:

- Traditional Water Extracts: Considered the safest preparation method, as harmful alkaloids are not efficiently extracted in water. Traditionally used in Pacific Island cultures, this method has been associated with low toxicity [30].
- Ethanol and Acetone Extracts: These commercial extracts yield higher kavalactone concentrations but may co-extract toxic alkaloids such as pipermethystine, increasing hepatotoxicity risks [31].
- Supercritical CO_2 Extraction: A modern technique producing high-purity kavalactones while minimizing toxic components. This method is increasingly preferred for pharmaceutical applications due to its improved safety profile [32].

The phytochemical profile of *Piper methysticum* is highly influenced by plant part selection, cultivar type, and extraction method. Noble cultivars remain the preferred choice for medicinal applications, while two-day cultivars and wild-type varieties present higher risks of hepatotoxicity. Future research should focus on optimizing extraction techniques, refining kavalactone-to-alkaloid ratios, and conducting long-term clinical trials to establish safe dosage guidelines. A standardized approach to kava consumption will be essential for maximizing therapeutic benefits while minimizing risks.

4. PHARMACOLOGICAL ACTIVITIES OF KAVA

4.1. Sedative and Hypnotic Effects of *Piper methysticum*

The sedative and hypnotic effects of *Piper methysticum* (kava) have been extensively studied, with increasing evidence suggesting that kavalactones interact with multiple neurochemical pathways to exert their calming effects. Unlike conventional sedatives such as benzodiazepines (e.g., Tranxene, Halcion), barbiturates, and antihistamines, which exert their effects primarily through direct modulation of γ-aminobutyric acid (GABA) receptors, kavalactones appear to work through non-traditional pathways, leading to a distinct sedative profile [1].

4.1.1. Mechanisms of Action Underlying Kava's Sedative Properties

Kavalactones, particularly kavain, dihydrokavain, methysticin, and dihydromethysticin, are thought to modulate neurotransmitter activity without directly binding to benzodiazepine or GABA-A receptor sites. However, emerging evidence suggests that kavalactones may enhance GABAergic transmission indirectly by increasing the availability of GABA binding sites or influencing receptor subunit composition [2]. This hypothesis is supported by studies showing that kavain and dihydromethysticin potentiate the effects of ipsapirone, a serotonin 5-HT1A receptor agonist with anxiolytic and sedative properties, suggesting an interplay between GABAergic and serotonergic systems in kava's mechanism of action [3]. In addition to its GABAergic effects, kava appears to modulate dopaminergic and glutamatergic signaling pathways, which may contribute to its tranquilizing effects. Early dopamine antagonist studies indicate that some of kava's calming effects may stem from interactions with dopaminergic pathways in the limbic system, particularly within the amygdala complex, which is heavily involved in emotion regulation and anxiety processing [4]. Furthermore, electrophysiological studies using hippocampal tissue from guinea pigs have demonstrated that kavain and dihydromethysticin enhance the effects of NMDA receptor antagonists, suggesting that kava may also regulate glutamate-mediated excitatory neurotransmission [5].

4.1.2 Electrophysiological and Behavioral Evidence of Sedation

Animal studies have consistently demonstrated kava's sedative and hypnotic effects across various models. For instance, treatment with kava extracts in rabbits induced significant electroencephalographic (EEG) changes that closely resembled those seen with traditional sedative-hypnotic medications [6]. These EEG alterations suggest that kava may influence sleep architecture, possibly by increasing slow-wave sleep (SWS) and rapid eye movement (REM) sleep, similar to but distinct from benzodiazepines and barbiturates [7]. Studies in mice and rats have further validated these findings. Dihydrokavain and dihydromethysticin administration resulted in dose-dependent sedation and hypothermia, indicating their potential role as CNS depressants [8]. In a rat model of hypermotility, kava resin was shown to reduce spontaneous locomotor activity, an effect comparable to that observed with antipsychotic drugs [9]. Additionally, kava extracts have been found to inhibit conditioned avoidance responses, suggesting a possible role in modulating cognitive and emotional reactivity [10].

4.1.3 Human Studies: EEG and Sleep Architecture Modulation

Human clinical trials have further explored kava's potential in enhancing sleep quality without the cognitive impairment typically associated with sedatives. In a 4-day, placebo-controlled study involving 12 healthy participants, subjects were administered either 300 mg (containing 210 mg kavalactones) or 150 mg (containing 105 mg kavalactones) of standardized kava extract, following a 3-day placebo period [11].

Key findings from this study included:

- Reduced wakeful periods during sleep cycles.
- Shortened light and deep sleep phases, suggesting improved sleep efficiency.
- Prolonged REM sleep duration, in contrast to benzodiazepines, which are known to suppress REM sleep.

These results indicate that kava may improve sleep architecture, making it a potentially useful alternative to pharmaceutical sedatives that often disrupt natural sleep cycles [12]. Moreover, increased sleep spindle density, a hallmark of stable sleep states, was observed in kava users, further supporting its role in promoting restful sleep [13].

4.1.4 Cognitive Effects: Preservation of Mental Clarity

One of the most notable distinctions between kava and traditional sedatives is its lack of cognitive impairment. Unlike benzodiazepines, which are known to reduce psychomotor function, impair

memory, and induce drowsiness, kava may actually enhance cognitive function in some cases. In a double-blind, placebo-controlled, crossover trial, 12 healthy participants were administered either oxazepam (a benzodiazepine) or standardized kava extract (600 mg/day for five days). The effects on cognitive function were evaluated using event-related potentials (ERPs) during a word recognition task. The results showed that:

- Kava did not impair reaction time or accuracy, while oxazepam significantly reduced both measures.
- Kava did not induce excessive drowsiness, in contrast to oxazepam, which caused sedation-related cognitive slowing.
- No decline in working memory or attention was observed in kava users, whereas benzodiazepine-treated participants exhibited notable deficits in these areas [14].

These findings suggest that kava's sedative properties are unique in that they promote relaxation without causing the cognitive dulling commonly associated with pharmaceutical anxiolytics and hypnotics.

4.1.5 Comparison to Standard Sedatives

Kava's unique pharmacological profile makes it a potential alternative to traditional sedativehypnotic medications, particularly in individuals who experience adverse effects with benzodiazepines, barbiturates, or antihistamines.

4.2 Cognitive Effects, Alcohol Interaction, and Neurophysiological Insights into Kava's Sedative Mechanism

Kava (*Piper methysticum*) has been widely studied for its unique sedative effects, which, unlike traditional anxiolytics such as benzodiazepines, appear to induce relaxation without cognitive impairment. Multiple clinical trials have investigated how kava influences cognitive function, mental alertness, and neurophysiological parameters, particularly when compared to standard pharmaceutical sedatives. While the precise mechanisms underlying kava's effects remain partially unclear, a growing body of research suggests that kavalactones may modulate neurotransmission through multiple pathways, influencing not only GABAergic activity but also dopaminergic, serotonergic, and limbic system functions [1].

4.2.1 Kava's Impact on Cognitive Performance and Mental Alertness: Clinical Findings

One of the most intriguing aspects of kava's pharmacological profile is its ability to promote relaxation while preserving, and in some cases even enhancing, cognitive function. A doubleblind, placebo-controlled study involving twelve healthy male participants investigated kava's effects using an event-related potential (ERP)-based visual search paradigm, which assesses attention allocation and cognitive processing efficiency. The results demonstrated that kava improved both attention allocation and information processing speed, whereas the benzodiazepine oxazepam significantly impaired these functions [2]. This suggests that kava exerts its calming effects through mechanisms distinct from those of conventional sedatives, which typically induce drowsiness and cognitive slowing. Further research has examined kava's interaction with alcohol, a substance well known for impairing reaction time, memory, and motor coordination. In a double-blind, placebo-controlled study involving 40 healthy participants, subjects were given standardized kava extract in combination with ethanol (resulting in a 0.05% blood alcohol concentration). Interestingly, while ethanol alone was found to reduce mental focus and cognitive performance, the addition of kava mitigated some of these detrimental effects, indicating a potential protective role in maintaining cognitive function under mild alcohol intoxication [3]. However, when tested in higher ethanol concentrations, kava's sedative and hypnotic effects were significantly amplified, leading to increased drowsiness and motor impairment in an animal model. These findings emphasize the importance of dose-dependent interactions between kava and alcohol, highlighting the need for further investigation into the neurochemical basis of this interaction [4].A randomized, double-blind, crossover clinical study directly compared the cognitive andsedative effects of kava (120 mg kavalactones) and diazepam (10 mg) against a placebo. Neurophysiological and psychophysiological assessments were conducted before, two hours after, and six hours after administration to evaluate mental alertness, reaction time, and attention span. Both kava and diazepam produced significant differences compared to placebo, but their effects were markedly different. Diazepam induced a clear decline in cognitive performance, impairing reaction time and working memory while increasing subjective feelings of drowsiness. Kava, on the other hand, was found to have a prolonged calming effect, which persisted up to six hours' post-administration, but without causing significant cognitive

impairment. Additionally, EEG analysis revealed no increase in beta-activity, a phenomenon commonly observed with benzodiazepines and associated with cognitive dulling and dependency risk [5].

4.2.2 The Paradox of Relaxation and Enhanced Performance: How Kava Differs from Traditional Sedatives

One of the most striking observations in kava research is its ability to reduce stress and anxiety while simultaneously improving performance on complex cognitive tasks. This seemingly contradictory effect has been verified in multiple psychophysiological studies. In one experiment, participants who consumed kava performed better on complex problem-solving tasks than those who received diazepam or a placebo [6]. Unlike traditional sedatives, which impair executive functioning and psychomotor coordination, kava appears to enhance cognitive efficiency while reducing physiological stress responses. This unique profile has led researchers to hypothesize that kava's mechanism of action does not rely solely on GABAergic modulation. Instead, it may involve dopaminergic and limbic system interactions, particularly in regions responsible for emotion regulation, motivation, and cognitive flexibility. Several studies suggest that kavalactones target limbic structures, including the amygdala and hippocampus, modulating their activity to produce a calming effect without excessive sedation [7].

4.2.3 Neurophysiological Studies on Kava: EEG, Brain Activity, and Limbic Modulation

Electroencephalographic (EEG) studies have provided valuable insights into how kava affects brainwave activity. Unlike benzodiazepines, which tend to suppress high-frequency brain waves (beta waves) and increase slow-wave activity (delta waves)—leading to mental sluggishness and impaired cognitive function—kava exhibits a distinct neurophysiological profile. In a study using rabbits treated with kava extracts, EEG readings displayed alterations in brain activity similar to those produced by sedative medications, but with preserved betawave function, suggesting a unique calming effect that does not induce excessive drowsiness or lethargy [8]. Further evidence from sleep studies suggests that kava may improve sleep quality by modulating REM sleep duration and deep sleep phases. Unlike benzodiazepines and barbiturates, which disrupt normal sleep architecture, kava has been observed to prolong REM sleep while maintaining deep sleep integrity, leading to more restorative sleep patterns [9]. These findings indicate that kava may have potential as a sleep aid, particularly for individuals suffering from stress-induced insomnia or anxiety-related sleep disturbances.

4.3 Interaction Between Kava and Other Anxiolytics: Potential Synergistic and Adverse Effects

Given its growing popularity as an alternative to prescription anxiolytics, researchers have also examined how kava interacts with pharmaceutical sedatives, particularly benzodiazepines. In a randomized, three-way crossover study, eighteen healthy volunteers were administered bromazepam (4.5 mg twice daily), kava (120 mg kavalactones twice daily), or a combination of the two. The study assessed seven cognitive performance measures, including visual orientation, prolonged concentration, auditory reaction time, stress tolerance, vigilance, and motor coordination. While kava alone had no adverse effects on vigilance, motor coordination, or cognitive function, the combination of bromazepam and kava resulted in significant fatigue and reduced cognitive performance [10]. These findings suggest that kava may not potentiate the sedative effects of benzodiazepines in a linear manner, but rather, the interaction depends on the specific neurochemical pathways involved. While co-administration does not appear to increase major risks, the additive sedative effect observed with bromazepam highlights the importance of careful dosage considerations, particularly in individuals using multiple CNS depressants.

4.4 Pharmacological Activities of *Piper methysticum*: The Role of Current Bioactive Compounds

Kava (Piper methysticum) has been extensively studied for its therapeutic potential, particularly due to its rich phytochemical profile, dominated by kavalactones, flavokavains, and various secondary metabolites. These compounds contribute to a wide spectrum of pharmacological effects, including analgesic, anxiolytic, anticonvulsant, neuroprotective, antiischemic, antithrombotic, antifungal, anticancer, and metabolic-modulating activities. Unlike synthetic pharmaceuticals that typically act on single-receptor mechanisms, kava-derived bioactive compounds influence multiple molecular pathways, making them valuable candidates for drug discovery and natural therapeutic applications. The following sections explore the pharmacodynamics of kava's bioactive compounds, their mechanisms of action, and their clinical relevance in the context of Current Bioactive Compounds research.

4.5 Analgesic and Local Anesthetic Effects: Non-Opiate Pain Modulation via Kavalactones

One of the most significant pharmacological properties of kava is its analgesic potential, which is primarily attributed to its kavalactone content, particularly kavain, dihydrokavain, and methysticin. Unlike conventional opioid analgesics, which function via μ-opioid receptor activation, kava-derived kavalactones appear to relieve pain through non-opiate mechanisms, reducing the risk of opioid dependence, withdrawal symptoms, and tolerance buildup. Studies have demonstrated that naloxone, a potent opioid antagonist, fails to reverse kava-induced analgesia, confirming that kavalactones operate through alternative pathways, primarily involving cyclooxygenase (COX) inhibition and ion channel modulation. Kavalactones have been shown to suppress both COX-1 and COX-2 enzyme activity. This mechanism makes kava particularly promising for treating chronic inflammatory conditions such as arthritis, fibromyalgia, and neuropathic pain disorders. Comparative studies indicate that dihydrokavain exhibits greater analgesic efficacy than aspirin, while its potency remains lower than that of morphine. However, when co-administered with aspirin, dihydrokavain and dihydromethysticin exhibit an additive analgesic effect, suggesting a potential synergistic interaction with nonsteroidal anti-inflammatory drugs (NSAIDs) to enhance pain relief while reducing NSAID-related side effects. In addition to its systemic analgesic effects, kava has demonstrated topical anesthetic properties, with certain kavalactones exhibiting potency comparable to cocaine and procaine. This has led to increased interest in developing kava based formulations for local pain management, particularly in dental procedures, post-surgical pain relief, and neuropathic pain syndromes. Interestingly, caffeine has been observed to reduce the duration but not the intensity of kava-induced analgesia, indicating potential interactions between kavalactones and adenosine receptor signaling. Future studies should explore how these phytochemical interactions may influence kava's analgesic efficacy in clinical applications.

4.6 Anxiolytic Effects: Modulation of GABAergic and Monoaminergic Neurotransmission

Kava has gained significant attention for its anxiolytic (anti-anxiety) effects, which have been validated through multiple randomized, placebo-controlled, double-blind clinical trials. Unlike benzodiazepines, which act as direct GABA-A receptor agonists, kavalactones exert their anxiolytic effects through a more complex, multi-receptor mechanism that involves GABAergic, dopaminergic, serotonergic, and glutamatergic pathways. One of the key bioactive mechanisms of kava's anxiolytic effect is its ability to inhibit monoamine oxidase B (MAO-B). Kavalactones such as desmethoxyyangonin and methysticin function as MAO-B inhibitors, increasing the synaptic availability of dopamine and serotonin, both of which play crucial roles in mood regulation, emotional stability, and cognitive function. This mechanism differentiates kava from benzodiazepines, as benzodiazepines induce tolerance and withdrawal effects, whereas kava retains its anxiolytic efficacy over prolonged use without significant dependence risks. Further evidence suggests that kava modulates GABAergic neurotransmission by indirectly influencing GABA-A receptor subunits, rather than binding directly to benzodiazepine sites. This mechanism allows for anxiety reduction without excessive sedation, making kava an ideal therapeutic option for individuals who need to manage stress while maintaining cognitive performance. Quantitative EEG studies in clinical trials have demonstrated that kava enhances relaxation without impairing cognitive function, and in some cases, has even been found to improve cognitive processing speed and attentional control. Recent neurophysiological research suggests that kava's anxiolytic effects may also involve regulation of glutamate and NMDA receptor activity, leading to reduced excitotoxicity and stress-related neuronal hyperactivity. These findings provide insight into why kava is effective in both acute and chronic anxiety conditions, as it appears to modulate neurotransmitter balance rather than inducing generalized CNS suppression. Given its unique neuropharmacological profile, kava is being explored as a potential alternative to benzodiazepines, SSRIs, and other pharmacological anxiolytics for treating generalized anxiety disorder (GAD) and stress-related mood disorders.

4.7 Neuroprotective and Anti-Ischemic Properties: Kavalactones as Potential Stroke Therapeutics

Recent research has highlighted kava's neuroprotective potential, particularly in the context of stroke rehabilitation, ischemic brain injury, and neurodegenerative disorders. Kavalactones such as methysticin and dihydrokavain have been shown to reduce neuronal damage following ischemic stroke by modulating glutamate excitotoxicity, oxidative stress, and mitochondrial function. Studies in animal models of

localized cerebral ischemia indicate that pre-treatment with kavalactones significantly reduces infarct size, enhances neuronal survival, and improves functional recovery post-stroke.

These findings suggest that kavalactones could serve as promising neuroprotective agents for mitigating post-stroke brain damage and potentially reducing the long-term cognitive deficits associated with cerebrovascular injury. Given that current pharmacological options for ischemic stroke recovery remain limited, further clinical trials investigating kava's potential as an adjunct neuroprotective therapy are warranted. The bioactive compounds of *Piper methysticum*, particularly kavalactones, flavokavains, and secondary alkaloids, exhibit a wide range of pharmacological activities, spanning from analgesic and anxiolytic effects to neuroprotection and anti-inflammatory properties. Unlike many synthetic drugs that target single pathways, kava exerts its effects through multi-receptor modulation, making it a versatile therapeutic candidate. Its ability to provide anxiety relief without cognitive impairment, reduce inflammatory pain without opioid dependence, and offer neuroprotection in ischemic conditions underscores its therapeutic potential. As research continues, standardized kava formulations may play an increasingly important role in integrative medicine, particularly in neurology, psychiatry, pain management, and stroke recovery.

5. CONCLUSION

Piper Methysticum is an important medicinal plant with a wide range of traditional and contemporary therapeutic uses. Kavalactones are primarily responsible for its pharmacological potential; they impact ion channels, inhibit MAO-B, and modify GABA receptors to provide sedative, anxiolytic, muscle-relaxant, and neuroprotective actions. Beyond these primary effects, kava is a multifaceted natural treatment that also has analgesic, anti-inflammatory, anticonvulsant, and anticancer qualities. However, a key element in determining its safety and effectiveness is the impact of plant parts. While aerial portions like stems and leaves contain flavokavains and alkaloids linked to hepatotoxicity, roots and rhizomes, which are rich in kavalactones, are most suited for medicinal usage. This emphasizes the necessity of better extraction techniques and the judicious utilization of plant material. In comparison to organic solvent procedures, water-based and CO_2 extractions are thought to be safer since they preserve bioactivity while lowering the danger of toxicity. Reports of liver damage highlight the significance of standardization, quality control, and thorough clinical validation despite its potential.Kava can be used as a safe and efficient herbal remedy for neurological and mental conditions with proper management and more study. All things considered, Piper methysticum is still a viable natural resource as long as safety and effectiveness are balanced by research and clinical data.

REFERENCES

1. Stevinson, C., Huntley, A., & Ernst, E. (2002). A systematic review of the safety of kava extract in the treatment of anxiety. *Drug Safety*, *25*, 251-261.

2. Sarris, J., Panossian, A., Schweitzer, I., Stough, C., & Scholey, A. (2011). Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. *Eur. Neuropsychopharmacol*, *21*(12), 841-860.

3. Schulz, V., Hänsel, R., & Tyler, V. E. (2001). *Rational phytotherapy: a physician's guide to herbal medicine*.*Psychol. Press*.

4. Elkins, G., Rajab, M. H., & Marcus, J. (2005). Complementary and alternative medicine use by psychiatric inpatients *Psychol. Rep*, *96*(1), 163-166.

5. Mischoulon, D. (2004). Nutraceuticals in psychiatry, part 2:review of six popular psychotropics. *Contemp. Psychiatry*, *3*(1), 1-8.

6. Sarris, J., McIntyre, E., & Camfield, D. A. (2013). Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence. *CNS drugs*, *27*(4), 301-319.

7. Burton, N., Sneed, K. B., & Pathak, Y. Systemic Review of the Use of Kava Kava for the Reduction of Anxiety Disorder.

8. Ernst, E. (2007). A re-evaluation of kava (Piper methysticum). *Br J Clin Pharmacol 64*(4), 415.

9. Jhoo, J. W., Freeman, J. P., Heinze, T. M., Moody, J. D., Schnackenberg, L. K., Beger, R. D., ... & Ang, C. Y. (2006). In vitro cytotoxicity of nonpolar constituents from different parts of kava plant (Piper methysticum). *J. Agric. Food Chem*, *54*(8), 3157-3162.

10. Whitton PA, Lau A, Salisbury A, Whitehouse J, Evans CS. Kavalactones and the kava-kava controversy. Phytochemistry 2003;64: 673–9.

11. Clough AR, Jacups SP, Wang Z. Health experts of kava use in an eastern Arnhem Land community.*Intern Med J*2003,336–40.

12. Ernst, E. (2007). A re-evaluation of kava (Piper methysticum). Br J Clin Pharmacol, *64*(4), 415.

13. Kenda, M., Kočevar Glavač, N., Nagy, M., & Sollner Dolenc, M. (2022). Medicinal plants used for anxiety, depression, or stress treatment: An update. *Molecules*, *27*(18), 6021.

14. Sarris, J. (2018). Herbal medicines in the treatment of psychiatric disorders: 10-year updated review. *Phytother. Res*, *32*(7), 1147-1162.

15. Singh, Y. N., & Singh, N. N. (2002). Therapeutic potential of kava in the treatment of anxiety disorders. *CNS drugs*, *16*, 731-743.

16. Bilia AR, Gallon S, Vincieri FF. Kava-kava and anxiety: growing knowledge about the efficacy and safety. *Life Sci* 2002; 70: 2581–2597.

17. Sarris, J., LaPorte, E., & Schweitzer, I. (2011). Kava: a comprehensive review of efficacy, safety, and psychopharmacology. *Aust N Z J Psychiatry*, *45*(1), 27-35.

18. Angerhofer, C.K., Maes, D. and Giacomoni, P.U. 2009. The use of natural compounds and botanicals in the development of anti-aging skin care products. Skin Aging Handbook, pp. 205263.

19. Annegowda, H. V., Mordi, M. N., Ramanathan, S., & Mansor, S. M. (2010). Analgesic and antioxidant properties of ethanolic extract of Terminalia catappa L. leaves. *Int. J. Pharmacol*, *6*(6), 910-915.

20. Ara, J., Sultana, V., Ehteshamul-Haque, S., Qasim, R., & Ahmad, V. U. (1999). Cytotoxic activity of marine macro-algae on Artemia salina (Brine shrimp). *Phytotherapy Research: Phytotherapy Research or PTR*, *13*(4), 304-307.

21. Minh, T. N., Van, T. M., Khanh, T. D., & Xuan, T. D. (2022). Isolation and identification of constituents exhibiting antioxidant, antibacterial, and antihyperuricemia activities in Piper methysticum root. *Foods*, *11*(23), 3889.

22. Bilia, A. R., Scalise, L., Bergonzi, M. C., &Vincieri, F. F. (2004). Analysis of kavalactones from Piper methysticum (kava-kava). *J. Chromatogr. B*, *812*(1-2), 203-214.

23. Dinh, L. D., Simmen, U., Bueter, K. B., Bueter, B., Lundstrom, K., & Schaffner, W. (2001). Interaction of various Piper methysticum cultivars with CNS receptors in vitro. *Planta Med*, *67*(04), 306-311.

24. Lebot, V., Do, T. K. T., & Legendre, L. (2014). Detection of flavokavins (A, B, C) in cultivars of kava (Piper methysticum) using high performance thin layer chromatography (HPTLC).*Food Chem*, *151*, 554-560.

25. Kuchta, K., de Nicola, P., & Schmidt, M. (2018). Randomized, dose-controlled double-blind trial: Efficacy of an ethanolic kava (Piper methysticum rhizome) extract for the treatment of anxiety in elderly patients. *TRADIT KAMPO MED*, *5*(1), 3-10.

26. Bian, T., Corral, P., Wang, Y., Botello, J., Kingston, R., Daniels, T., ... & Xing, C. (2020). Kava as a clinical nutrient: promises and challenges. *Nutrients*, *12*(10), 3044.

27. Sarris, J., Kavanagh, D. J., Byrne, G., Bone, K. M., Adams, J., & Deed, G. (2009). The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. *Psychopharmacol*, *205*, 399-407.

28. Teschke, R., Sarris, J., &Lebot, V. (2011). Kava hepatotoxicity solution: A six-point plan for new kava standardization. *Phytomedicine*, *18*(2-3), 96-103.

29. Jaiswal, Y., Shaikh, M. F., Wang, I., Yong, Y., Lin Lin Lee, V., & Williams, L. (2020). Evaluation of anti-convulsive properties of aqueous kava extract on zebrafish using the PTZ-induced seizure model. *Brain Sci*, *10*(8), 541.

30. Stevinson, C., Huntley, A., & Ernst, E. (2002). A systematic review of the safety of kava extract in the treatment of anxiety. *Drug Saf*, *25*, 251-261.

31. Bilia, A. R., Gallori, S., &Vincieri, F. F. (2002). Kava-kava and anxiety: growing knowledge about the efficacy and safety.*Life Sci*., *70*(22), 2581-2597.

32. Smith, R. M., Thakrar, H., Arowolo, T. A., & Shafi, A. A. (1984). High-performance liquid chromatography of kava lactones from Piper methysticum. *J. Chromatogr. A*, *283*, 303-308.

33. Sarris, J., LaPorte, E., & Schweitzer, I. (2011). Kava: a comprehensive review of efficacy, safety, and psychopharmacology *Aust N Z J Psychiatry*, *45*(1), 27-35.

34. White, C. M. (2018). The pharmacology, pharmacokinetics, efficacy, and adverse events associated with kava. *J. Clin. Pharmacol*, *58*(11), 1396-1405.

35. Backhauß C., Krieglstein J. Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents. Eur. J. Pharmacol. 1992;215:265–269. doi: 10.1016/0014- 2999(92)90037-5. [PubMed] [CrossRef] [Google Scholar]

36. Hegazy, N. H., Breitinger, H. G., & Breitinger, U. (2019). Kavalactones from Kava (Piper methysticum) root extract as modulators of recombinant human glycine receptors. *Biol. Chem*, *400*(9), 1205-1215.

37. Kong, Y., Gao, X., Wang, C., Ning, C., Liu, K., Liu, Z., ... & Meng, Q. (2018). Protective effects of yangonin from an edible botanical Kava against lithocholic acid-induced cholestasis and hepatotoxicity.*Eur. J. Pharmacol*, *824*, 64-71.

38. Kuo, Y. F., Su, Y. Z., Tseng, Y. H., Wang, S. Y., Wang, H. M., & Chueh, P. J. (2010). Flavokawain B, a novel chalcone from Alpinia pricei Hayata with potent apoptotic activity: Involvement of ROS and GADD153 upstream of mitochondria-dependent apoptosis in HCT116 cells.*FRBM*, *49*(2), 214-226.

39. Tang, Y., & Fields, C. (2019). A UHPLC-UV method development and validation for determining kavalactones and flavokavains in Piper methysticum (kava). *Molecules*, *24*(7), 1245.

40. Liu, Y., Lund, J. A., Murch, S. J., & Brown, P. N. (2018). Single-lab validation for determination of kavalactones and flavokavains in Piper methysticum (kava). Planta Med, *84*(16), 1213-1218.

41. Teschke, R., Sarris, J., &Lebot, V. (2011). Kava hepatotoxicity solution: A six-point plan for new kava standardization. *Phytomedicine*, *18*(2-3), 96-103.

42. Dragull, K., Yoshida, W. Y., & Tang, C. S. (2003). Piperidine alkaloids from Piper methysticum. *Phytochem 63*(2), 193-198.

43. Dinh, L. D., Simmen, U., Bueter, K. B., Bueter, B., Lundstrom, K., & Schaffner, W. (2001). Interaction of various Piper methysticum cultivars with CNS receptors in vitro. *Planta Med, 67*(04), 306-311.

44. Lebot, V., Do, T. K. T., & Legendre, L. (2014). Detection of flavokavins (A, B, C) in cultivars of kava (Piper methysticum) using high performance thin layer chromatography (HPTLC).*Food Chem*, *151*, 554-560.

45. Kuchta, K., de Nicola, P., & Schmidt, M. (2018). Randomized, dose-controlled double-blind trial: Efficacy of an ethanolic kava (Piper methysticum rhizome) extract for the treatment of anxiety in elderly patients. *TRADIT KAMPO MED*, *5*(1), 3-10.

46. Bian, T., Corral, P., Wang, Y., Botello, J., Kingston, R., Daniels, T., ... & Xing, C. (2020). Kava as a clinical nutrient: promises and challenges. *Nutrients*, *12*(10), 3044.

47. Sarris, J., Kavanagh, D. J., Byrne, G., Bone, K. M., Adams, J., & Deed, G. (2009). The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. *Psychopharmacol*, *205*, 399-407.

48. Teschke, R., Sarris, J., &Lebot, V. (2011). Kava hepatotoxicity solution: A six-point plan for new kava standardization. *Phytomedicine*, *18*(2-3), 96-103.

49. Lebot, V., Do, T. K. T., & Legendre, L. (2014). Detection of flavokavins (A, B, C) in cultivars of kava (Piper methysticum) using high performance thin layer chromatography (HPTLC). *Food Chem*, *151*, 554-560.

50. Lobo, V., Patil, A., Phatak, A., & Chandra, N. (2010). Free radicals, antioxidants and functional foods: Impact on human health. *Phcog Rev.*, *4*(8), 118.